Xylazine

Overview

Xylazine (Rompun®, Sedaxylan®, Virbaxyl®) is an alpha-2-adrenergic agonist used in veterinary medicine to provide dose-dependent sedation, muscle relaxation, and short-duration analgesia in dogs and cats. It may be administered alone or combined with other anesthetic or analgesic agents for sedation and preanesthetic protocols.

In small animal practice, xylazine has largely been replaced by medetomidine and dexmedetomidine because of its lower alpha-2 receptor selectivity and less favorable safety profile. Xylazine can produce significant cardiovascular effects and increases myocardial sensitivity to catecholamine-associated arrhythmias.

Mechanism of Action (MOA): Xylazine acts primarily as a central and peripheral alpha-2-adrenergic receptor agonist. Activation of central alpha-2 receptors suppresses norepinephrine release, producing sedation, muscle relaxation, and analgesia. Peripheral alpha receptor effects contribute to cardiovascular changes including vasoconstriction, bradycardia, and altered blood pressure.

Receptor selectivity (alpha-2 : alpha-1) ranks xylazine at 160:1, detomidine 260:1, romifidine 340:1, and medetomidine / dexmedetomidine 1620:1. The lower ratio drives more peripheral alpha-1 effects (vasoconstriction, reflex bradycardia, arrhythmia sensitivity) and explains the less favourable safety profile compared with newer alpha-2 agonists.

Timing: IV onset 3–5 min, IM/SC 10–15 min · analgesia 15–30 min only · sedation 1–2 h (dose-dependent) · dog serum half-life ~30 min (20–40 min from a bolus) · full recovery 2–4 h. Plan procedures so the painful step finishes within the analgesic window — do not expect xylazine to carry pain control past the first half-hour.

Shares morphine-like analgesic actions but, unlike opioids, does NOT cause CNS excitation — it produces sedation and CNS depression instead. Useful when opioid-induced excitement is a concern.

Indications

Xylazine is used in dogs and cats as a sedative, preanesthetic medication, and short-acting analgesic agent. Although newer alpha-2 agonists are now more commonly preferred, xylazine may still be used in selected clinical situations.

• Sedation and restraint: Used to provide dose-dependent sedation and muscle relaxation during handling, diagnostic procedures, and minor interventions.
• Preanaesthetic medication: Administered alone or combined with opioids or anesthetic agents to facilitate anesthetic induction and reduce anesthetic dose requirements.
• Short-duration anaesthesia: Commonly combined with ketamine to provide short injectable anesthetic protocols for brief procedures.
• Adjunctive analgesia: Provides a short period of analgesia in addition to sedation.
• Emesis induction in cats: May be used to induce vomiting after ingestion of selected non-caustic toxic substances when emesis is appropriate.
• Anxiolytic use (cats): Low extra-label doses may be used for calming effects in selected patients.
• Growth hormone testing: Used in specialized endocrine protocols to assess pituitary growth hormone response.
• Cat emesis caveat — one dose only : Cat emesis caveat — ONE dose only; repeat doses depress the vomiting centre

Dosage (Reference)

Dog

In dogs, xylazine is used primarily for sedation and preanesthetic medication. Lower extra-label doses are commonly preferred clinically to reduce adverse cardiovascular effects.

Cat

In cats, xylazine may be used for sedation, preanesthetic medication, anxiolysis, or induction of emesis in selected toxic ingestion cases.

Warnings & Precautions

Xylazine is a potent alpha-2-adrenergic agonist associated with significant cardiovascular and systemic effects. Careful patient selection and monitoring are essential during administration.

• Cardiovascular disease: Do not use in patients with cardiovascular disease, shock, or impaired cardiovascular function due to the risk of severe bradycardia, arrhythmias, and blood pressure alterations.
• Reduced receptor selectivity: Xylazine is less alpha-2 selective than medetomidine or dexmedetomidine and is associated with a less favorable safety profile.
• Arrhythmogenic potential: Sensitization of the myocardium to catecholamines may increase the risk of cardiac arrhythmias and cardiovascular complications.
• Pregnancy: Avoid use in pregnant animals because xylazine increases uterine motility.
• Geriatric patients: Use in geriatric animals is generally not recommended because of increased sensitivity to sedative and cardiovascular effects.
• Diabetes mellitus: Avoid or use cautiously in diabetic patients due to effects on endogenous insulin secretion and blood glucose regulation.
• Vomiting precautions: Do not induce emesis in unconscious animals, patients with impaired airway protection, or after ingestion of caustic or petroleum-based substances.
• Respiratory and CNS depression: Higher doses or concurrent sedatives may increase the risk of excessive sedation, hypothermia, and respiratory depression.
• Spontaneous arousal: Strong external stimulation may abruptly interrupt sedation; aggressive animals should still be handled cautiously.
• Sympathomimetic drugs: Avoid concurrent use with sympathomimetic amines because of increased cardiovascular risk.
• Dehydrated / debilitated / urinary obstruction — additional CIs: Additional contraindications — dehydrated, debilitated, or urinary tract obstruction patients. Do NOT use.
• Avoid intracarotid injection: If a needle aimed at the jugular enters the carotid artery instead, even a small xylazine dose causes immediate severe seizures and collapse. Confirm vein placement before injecting.
• Pre-existing seizure disorders — extreme caution: Pre-existing seizure disorders — use with EXTREME caution. Xylazine itself can trigger seizures at overdose; a known epileptic patient is at higher risk.
• Decreased tear production (dogs): Apply artificial tears during and after sedation, especially for procedures >15 min or in dogs at risk of corneal ulceration (brachycephalic breeds, KCS history).
• Brachycephalic dogs — dyspnoea risk: Brachycephalic dogs — muscle relaxation may produce DYSPNOEA in patients with already-compromised upper-airway anatomy (pugs, French/English bulldogs, etc). Consider an alternative sedative or have airway-rescue equipment ready.
• Expanded emesis-induction CI list: Foreign body, raised intraocular pressure, strong acid or alkali ingestion, ingestion >2 h ago, paraffin / petroleum / oily / volatile organic products, unconscious / fitting / reduced cough reflex.
• Pregnancy mechanism + cesarean fetal-survival risk: Pregnancy mechanism — xylazine impairs uterine blood flow during gestation and may decrease fetal O2 delivery, especially in late gestation. reduced fetal survival rates when used as cesarean premedication. Heparin / opioid-sparing protocols are safer in late-pregnancy patients.

Drug Interactions

Clinically significant interactions with xylazine are primarily related to additive CNS depression, cardiovascular effects, and altered anesthetic requirements. Careful dose adjustment and monitoring are recommended when xylazine is combined with the following medications.

• General anaesthetic agents: Xylazine significantly reduces the dose requirements of induction and maintenance anesthetic agents.
• Opioids: Concurrent use enhances sedation and may increase the risk of cardiovascular and respiratory depression.
• Other sedatives and tranquilisers: Additive CNS depression and prolonged recovery may occur when combined with other sedative medications.
• Other alpha-2 agonists: Concurrent administration with other alpha-2 agonists may result in excessive sedation, bradycardia, and cardiovascular depression.
• Alpha-2 antagonists (reversal): Reverse or antagonize the sedative and cardiovascular effects of xylazine.
• Sympathomimetic amines: Concurrent use may increase the risk of arrhythmias and cardiovascular complications.
• Cardiovascular depressant drugs: Concurrent administration may potentiate hypotension, bradycardia, and reduced cardiac output.
• Ketamine: Commonly combined with xylazine for short-duration injectable anesthesia; cardiovascular and recovery effects should be monitored closely.
• Acepromazine — additive hypotension: Additive hypotension after the initial hypertensive phase; manufacturer warns AGAINST tranquiliser combinations. should NOT ordinarily be used with phenothiazines because of cardiac depression + vasodilation.
• Anticholinergics (atropine / glycopyrrolate): Concurrent use with alpha-2 agonists may significantly INCREASE BP, HR, and arrhythmia incidence, particularly at higher alpha-2 doses. Routine atropine premedication is discouraged. Treat symptomatic bradycardia only.
• Antiemetics — blunt cat emesis: Antiemetics (maropitant, metoclopramide, ondansetron) — may DECREASE the emetogenic effect of xylazine. Relevant when xylazine is used to induce emesis in cats: hold the antiemetic until emesis is achieved.
• Chloramphenicol — prolonged sedation: Prolonged sedation and GI stasis possible.
• Benzodiazepines: Diazepam, midazolam, and other benzos cause additive CNS depression with xylazine. Reduce doses of both.
• Epinephrine — ventricular arrhythmias: Epinephrine + xylazine (± halothane) — markedly raises VENTRICULAR ARRHYTHMIA risk. Distinct from the general ‘sympathomimetics’ bullet; pick a different sympathomimetic if one is needed during xylazine sedation.

Side Effects & Overdose

Side Effects

Adverse effects of xylazine are primarily related to its cardiovascular, respiratory, and CNS depressant actions. Effects are dose-dependent and may be more pronounced in compromised patients.

• Bradycardia: Common and clinically significant due to reduced sympathetic outflow.
• Hypotension: Blood pressure alterations may occur following initial vasoconstriction.
• Cardiac arrhythmias: Increased myocardial sensitivity to catecholamines may predispose patients to arrhythmias.
• Respiratory depression: Reduced respiratory rate and depth may occur, especially when combined with other sedatives or anesthetics.
• Vomiting: Common in cats and may occur shortly after administration.
• Diuresis: Increased urine production may occur secondary to suppression of ADH release.
• Hyperglycaemia: Transient increases in blood glucose may occur because of decreased endogenous insulin secretion.
• Hypothermia: Sedated patients may develop decreased body temperature during recovery.
• CNS depression: Excessive sedation or prolonged recovery may occur, particularly at higher doses.
• Decreased tear production (dogs): xylazine reduces tear production in dogs in a dose-related manner. Apply artificial tears during and after sedation, especially for procedures >15 min.
• Cardiac output drop up to 30%: cardiac output can drop by up to 30% — meaningful tissue-perfusion compromise beyond just bradycardia and hypotension. Watch geriatric and CV-compromised patients especially closely.
• Muscle tremors + auditory-stimulus arousal: Muscle tremors + arousal to sharp auditory stimuli — keep recovery quiet. Even apparently deeply sedated patients may twitch and respond.
• Sinoatrial + 1st-degree AV block: Cardiac effects can include sinoatrial block, first- and second-degree atrioventricular block, bradycardia, and sinus arrhythmia.
•  Ocular effects: It causes mydriasis and decreased intraocular pressure but In dogs, clinical doses decrease tear production in a dose-related manner but do not affect intraocular pressure and pupil size.

Overdose

Xylazine overdose may result in profound cardiovascular and CNS depression. Severity increases when combined with other sedatives, opioids, or anesthetic agents.

• Severe bradycardia: Marked slowing of heart rate may lead to poor tissue perfusion.
• Hypotension and cardiovascular collapse: Severe overdose may result in circulatory failure and shock.
• Profound sedation: Deep CNS depression, stupor, or coma may occur.
• Respiratory compromise: Severe respiratory depression or apnea may develop in advanced intoxication.
• Hypothermia: Significant decreases in body temperature may occur during prolonged sedation.
• Management: Treatment is primarily supportive and includes cardiovascular monitoring, oxygen support, fluid therapy, and temperature management.
• Reversal agents: Alpha-2 antagonists such as atipamezole or yohimbine may be used when clinically appropriate.
• Seizures reported after overdose: Seizures reported after xylazine overdoses — have IV diazepam or midazolam ready when treating an overdose patient.
• Overdose-level cardiac arrhythmias: cardiac arrhythmias as an overdose finding — distinct from clinical-dose bradycardia. ECG monitoring is essential; treat life-threatening arrhythmias as the rhythm dictates.
• 24-h veterinary poison consultation: Call a 24-h veterinary poison control centre for any suspected xylazine overdose — individualised reversal and supportive-care advice.

Key Notes

Practical clinical points that help optimize the safe and effective use of xylazine in dogs and cats in everyday veterinary practice:

• Short duration of action: Sedation and analgesia are relatively short-lived compared with many modern sedative protocols.
• Less commonly preferred: Xylazine has largely been replaced in small animal practice by medetomidine and dexmedetomidine because of improved receptor selectivity and safety.
• Useful ketamine combination: Xylazine-ketamine combinations remain useful for brief injectable anesthetic procedures.
• Rapid emetic effect in cats: Vomiting typically occurs quickly after administration when used for emesis induction.
• Dose-dependent effects: Sedation, analgesia, and cardiovascular depression increase as dose increases.
• Recovery quality varies: Some patients may recover smoothly while others experience excitement or sudden responsiveness during recovery.
• Monitoring is essential: Continuous cardiovascular and respiratory monitoring improves safety during sedation and recovery.
• Procedure planning: The relatively short anesthetic and analgesic duration should be considered when selecting procedures and recovery timing.
• PK timing pearl — onset / duration / recovery: Timing pearl — IV onset 3–5 min, IM/SC 10–15 min, analgesia 15–30 min, sedation 1–2 h, dog t½ ~30 min . full recovery 2–4 h. Plan procedures so the painful step fits in the analgesic window.
• No-atropine pearl: Do NOT premedicate with atropine to pre-empt xylazine bradycardia. concurrent anticholinergic + alpha-2 raises BP/HR/arrhythmia. Treat bradycardia only if symptomatic.
• Strength safety — 20 mg/mL only: Strength safety — stock and use ONLY the 20 mg/mL injection in small-animal practice. 100 mg/mL is large-animal concentration; the 5× confusion is a real overdose risk.
• Reversal pearls (atipamezole vs tolazoline vs yohimbine): Atipamezole is the cleanest sedation reversal (alpha-2 selective, less hypotensive than yohimbine). For reversing the EMETIC effect specifically in cats, tolazoline may be SUPERIOR. Reversing sedation also reverses analgesia — if the procedure was painful, give an alternative analgesic before reversing.